Corcept Therapeutics
CORT
NASDAQ
IPO2004
about CORT
Corcept Therapeutics develops innovative treatments for serious metabolic and endocrine diseases, including its flagship product for conditions such as Cushing's syndrome.
| type | open | high | low |
market cap |
volume |
|---|---|---|---|---|---|
| stock | $73.37 | $74.77 | $72.25 | $7.64B | 713.79K |
| eps |
price to earnings |
price to sales |
operating margin |
profit margin |
yield |
| +$0.33 | 65.45 | 48.27 | 13.72% | 18.08% | 0% |